|
Title
|
Status
|
|
|
Recruiting
in 22 of 23 locations
|
|
To determine if Accelerated Partial Breast Irradiation, using 3D CRT, is as effective as
Whole Breast Irradiation following breast conserving surgery in women with an new
histological diagnosis of ductal carcinoma in situ only or invasive breast cancer without
evidence of metastatic disease. Effectiveness will be determined by the rate of ipsilateral
breast tumour recurrence.
General objective is to improve the convenience and quality of life of female patients who
receive breast irradiation.
|
|
|
Recruiting
in 4 of 4 locations
|
|
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in
different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer
growth in different ways. Some block the ability of cancer cells to grow and spread. Others
find cancer cells and help kill them or carry cancer-killing substances to them.
Lenalidomide may stimulate the immune system in different ways and stop cancer cells from
growing. Giving fludarabine and rituximab together with lenalidomide or cyclophosphamide may
kill more cancer cells.
PURPOSE: This randomized phase II trial is studying fludarabine and rituximab to compare how
well they work with or without lenalidomide or cyclophosphamide in treating patients with
symptomatic chronic lymphocytic leukemia.
|
|
|
Recruiting
in 3 of 4 locations
|
|
The objective of this study is to compare the long-term efficacy of pasireotide LAR vs. octreotide LAR in controlling diarrhea and flushing in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by the maximum approved doses of somatostatin analogues.
|
|
|
Recruiting
in 6 of 7 locations
|
|
The primary goal of this study is to determine the rate of confirmed best cumulative
complete molecular response within the first year of study therapy with imatinib or
nilotinib. The study will also explore the impact and significance of the achieved CMR on
patient outcomes (PFS, EFS and OS), characterize the kinetics of CMR achieved in both
treatment arms and after the cross-over.
|
|
|
Recruiting
in 13 of 18 locations
|
|
RATIONALE: Sunitinib and sorafenib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib
or sorafenib after surgery may kill any tumor cells that remain after surgery. It is not yet
known whether sunitinib is more effective than sorafenib or placebo in treating kidney
cancer.
PURPOSE: This randomized phase III trial is studying sunitinib to see how well it works
compared to sorafenib or placebo in treating patients with kidney cancer that has been
removed by surgery.
|
|
|
Recruiting
in 3 of 3 locations
|
|
The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.
|
|
|
Recruiting
in 11 of 11 locations
|
|
This study will evaluate efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST).
|
|
|
Recruiting
in 3 of 4 locations
|
|
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as measured by progression free survival (PFS) compared to standard chemotherapy (Paclitaxel or Doxorubicin) in women with advanced endometrial cancer that progressed after first line chemotherapy.
|
|
|
Recruiting
in 1 of 1 locations
|
Hypothesis: The reduction of total body iron by phlebotomy will be safe and feasible in the post-HSCT setting
Iron overload is common after hematopoietic stem cell transplantation. It is associated with chronic liver disease, with increased rates of infection and decreased survival.
Eligible, consenting patients will have once monthly phlebotomy procedures (500ml) for 12 months.
SAFETY: At each visit, patients will have a comprehensive assessment prior to starting and after completing the phlebotomy. This assessment will include determination of pain at phlebotomy site, local infection and an assessment of symptoms of anemia including presyncope, fatigue and dyspnea. The patient's pulse, blood pressure, respiratory rate and temperature will also be determined before and following the phlebotomy.
EFFICACY: Iron stores will be measured serially in each patient. Measurements will be performed prior to the start of phlebotomy, and at 6 months and 12 months following the start of the series of 12 phlebotomies. These evaluations will be undertaken regardless of the number of phlebotomies which the patient actually undergoes. Iron stores will be estimated by measuring serum ferritin and transferrin saturation levels. Total body iron will be estimated from hepatic and cardiac iron concentration as measured by magnetic resonance imaging (MRI). Gandon et al. (12) described a non-invasive technique using MRI to measure hepatic iron stores. Iron is a paramagnetic substance which causes local magnetic field inhomogeneities leading to dephasing and signal loss in MRI. Gradient echo sequences are most susceptible to their effects because they do not use a 180° refocusing pulse, unlike conventional spin-echo sequences. Gandon et al. used multiple gradient echo sequences, compared the signal in liver to adjacent muscle and used this ratio to correlate with hepatic iron levels measured on tissue biopsy samples using spectrophotometric analysis. Multiple sequences were used because the nomogram comparing the L/M signal ratio is linear over only a small concentration of tissue iron.
|
|
|
Recruiting
in 8 of 8 locations
|
Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
This randomized phase III trial is studying memantine to see how well it works compared to a placebo in preventing side effects caused by whole-brain radiation therapy in patients with brain metastases from solid tumours.
|
